To verify if oncogenic KRAS augments bioavailable Cu levels in human CRC cells, we evaluated CCS and ATP7A levels in KRAS wild-type (CACO-2) and KRAS-mutated (HCT116, DLD-1, SW480, and SW620) cells. This evidence concerns the gene CCS and colorectal carcinoma.